The prognosis of adult T-cell leukemia/lymphoma (ATL) with primary central nervous system (CNS) involvement has been unclear since the advent of new therapies. Recently, we have shown that flow cytometric CD7/CADM1 analysis of CD4 + cells (HAS-Flow) is useful to detect ATL cells that are not morphologically diagnosed as ATL cells. We investigated the role of CNS involvement in ATL using cytology and HAS-Flow by analyzing cerebrospinal fluid (CSF) from 73 aggressive ATL cases. Based on the findings in CSF, the study subjects were classified into CNS + (cytologically malignant, n = 18), CNS- (cytologically non-malignant and ATL cell population negative in HAS-Flow, n = 44), and CNS-Micro (cytologically non-malignant and ATL cell population positive in HAS-Flow, n = 11) groups. As expected, the CNS + group had a shorter overall survival than the CNS- groups (P < 0.001). However, the CNS-Micro group showed no adverse impact on overall survival compared to the CNS- group (P = 0.506), even without additional CNS-targeted treatments. HAS-Flow also demonstrated clinical utility in the diagnosis of CSF lesions in ATL patients with cerebral white matter lesions and in the detection of ATL cells on post-treatment CSF examination in patients with CNS involvement. Our study demonstrates that ATL with CNS involvement have a poor prognosis and that CSF HAS-Flow is useful to assist in the diagnosis of suspected CNS involvement and to detect ATL cells with high sensitivity after treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00277-025-06186-4 | DOI Listing |
Ann Hematol
January 2025
Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
The prognosis of adult T-cell leukemia/lymphoma (ATL) with primary central nervous system (CNS) involvement has been unclear since the advent of new therapies. Recently, we have shown that flow cytometric CD7/CADM1 analysis of CD4 + cells (HAS-Flow) is useful to detect ATL cells that are not morphologically diagnosed as ATL cells. We investigated the role of CNS involvement in ATL using cytology and HAS-Flow by analyzing cerebrospinal fluid (CSF) from 73 aggressive ATL cases.
View Article and Find Full Text PDFCombined immune checkpoint blockade (ICB) and chemoradiation (CRT) is approved in patients with locally advanced cervical cancer (LACC) but optimal sequencing of CRT and ICB is unknown. NRG-GY017 (NCT03738228) was a randomized phase I trial of atezolizumab (anti-PD-L1) neoadjuvant and concurrent with CRT (Arm A) vs. concurrent with CRT (Arm B) in patients with high-risk node-positive LACC.
View Article and Find Full Text PDFBlood Adv
December 2024
H. Lee Moffitt Cancer Center, Tampa, Florida, United States.
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of CAR T in older adults and frail patients with RRMM. In this study, we utilized data from the Center for International Blood and Marrow Transplantation Registry to describe the safety and efficacy of ide-cel in these clinically important subgroups.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Background: In Alzheimer's disease (AD), a major gap remains in the understanding of how the interplay between peripheral and central immune systems drives neuroinflammation and disease progression. More recently, the concept of brain lymph drainage has sparked interest as it may shed light on how the dynamics of T cell interactions contribute to AD. Our preliminary study aims to characterize alterations in the peripheral blood lymphocyte population among individuals with AD-dementia and mild cognitive impairment (MCI), as compared with cognitively unimpaired (CU) individuals.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Florida College of Medicine, Gainesville, FL, USA.
Background: Peripheral blood mononuclear cells (PBMCs) were obtained from patients across different stages of Parkinson's disease (PD) progression and stimulated ex vivo to develop biomarkers for predicting PD progression.
Method: PBMCs obtained at one time-point from patients with moderate stage PD (>5 years after diagnosis) (n = 30), early stage PD (<5 years after diagnosis) (n = 27), prodromal PD (rapid-eye-movement sleep behavior disorder patients) (n = 14), and healthy controls (HCs) (n = 9) were isolated from whole blood and cryopreserved. Samples were thawed, then pan-monocytes and T-cell populations were isolated from PBMCs and subjected to treatment with vehicle or IFN-γ.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!